Snapshot from Sep 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Business IPO

JATT III Acquisition Corp IPO Pricing

Analysis based on 11 articles · First reported Aug 25, 2026 · Last updated Aug 26, 2026

Sentiment
30
Attention
2
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The IPO provides BHAV Acquisition Corp with $60 million in gross proceeds to fund a future business combination, adding to the pipeline of healthcare-focused SPACs in the market. Investor interest in biotech and life sciences SPACs may be positively influenced by this offering, though the impact is limited given the company's early stage and lack of a target.

Financial Services Biotechnology Healthcare

BHAV Acquisition Corp, a newly formed special purpose acquisition company (SPAC) incorporated in the United Kingdom — Cayman Islands, priced its initial public offering of 6,000,000 ordinary shares at $10.00 per share, raising $60 million in gross proceeds. The shares are expected to begin trading on the Nasdaq Capital Market Capital Market under the ticker symbol 'JTTT' on August 26, 2026, with the offering expected to close on August 27, 2026. Guggenheim Partners, LLC is acting as sole book-running manager, and the company has granted underwriters a 45-day option to purchase up to 900,000 additional shares to cover over-allotments. The registration statement was declared effective by the United States — United States Securities and Exchange Commission on August 25, 2026. The company has not yet identified a business combination target but intends to focus on healthcare and life sciences, particularly biotechnology and data-driven approaches such as machine learning and computational biology. The SPAC is sponsored by JATT Ventures III L.P. and led by CEO and Chairman Dr. Someit Sidhu, CFO Nicholas Fernandez, and board members Verender S. Badial, Arjun Goyal, Jonathon Kluft, and Christopher Staral.

100 BHAV Acquisition Corp completed initial public offering
30 BHAV Acquisition Corp granted over-allotment option Guggenheim Partners
stock
The company successfully priced its IPO, raising $60 million to pursue a business combination in healthcare and life sciences. This event marks its debut on Nasdaq Capital Market and provides capital for future acquisitions.
Importance 100.0 Sentiment 50.0
priv
Acting as sole book-running manager, Guggenheim Partners facilitated the IPO and received an over-allotment option, generating underwriting fees and strengthening its role in the SPAC market.
Importance 80.0 Sentiment 40.0
govactor
The SEC declared the registration statement effective, enabling the IPO to proceed. This regulatory approval is a routine but essential step for the offering.
Importance 70.0 Sentiment 20.0
priv
As the sponsor, JATT Ventures III L.P. will benefit from the IPO proceeds and potential future business combination, aligning its interests with the SPAC's success.
Importance 70.0 Sentiment 40.0
exch
The Nasdaq Capital Market Capital Market will list JATT III's shares under the ticker 'JTTT', adding another SPAC to its exchange and benefiting from listing fees and trading activity.
Importance 60.0 Sentiment 30.0
per
As CEO and Chairman, Dr. Sidhu leads the SPAC and will guide its search for a target, leveraging his experience in biotechnology and capital markets.
Importance 60.0 Sentiment 30.0
per
As CFO, Fernandez oversees the financial aspects of the SPAC, including the IPO proceeds and future transaction structuring.
Importance 50.0 Sentiment 20.0
loc
As the incorporation jurisdiction, the United Kingdom — Cayman Islands provides a favorable legal and tax environment for the SPAC, though the event has minimal direct impact on the jurisdiction itself.
Importance 40.0 Sentiment 10.0
per
As a board member, Badial contributes to the SPAC's strategic direction and target selection, though his role is supportive.
Importance 30.0 Sentiment 10.0
per
As a board member, Goyal provides expertise in biotechnology investing, aiding the SPAC's focus on life sciences.
Importance 30.0 Sentiment 10.0
per
As a board member, Kluft brings experience in company architecture and capital markets, supporting the SPAC's operations.
Importance 30.0 Sentiment 10.0
per
As a board member, Staral contributes to the SPAC's governance and strategic decisions, though his role is secondary.
Importance 30.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.